TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06745908: Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Sma

Sponsor: ImmunityBio, Inc. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 507 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,772,230

Rescue Site Savings

+$2,498,490

Unlock Full NCT06745908 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06745908 Rescue Dossier →